AvailableExpanded AccessLast updated Aug 12, 2026

EAP for Deucrictibant Immediate-release

Expanded Access for Deucrictibant IR Capsule

Overview

ClinicalTrials.gov ID: NCT07759141
Lead Sponsor: Pharvaris Netherlands B.V.INDUSTRY
Brief Summary: This is an expanded access program (EAP) designed to allow access to deucrictibant immediate-release (IR) capsule for eligible participants with hereditary angioedema (HAE) in the United States (US) and US territories who lack satisfactory alternative treatment options for on-demand treatment of HAE attacks, as determined by their treating physician.
Study Type

Status

Overall Status: Available
Start Date: No data available
Primary Completion Date: No data available
Completion Date: No data available

Study Record Dates

First Submitted: Aug 5, 2026
First Submitted that Met QC Criteria: Aug 5, 2026
First Posted: Aug 12, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 5, 2026
Last Update Posted: Aug 12, 2026Actual
Last Verified: Aug 2026

NCT06679881Recruiting

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06669754Active, not recruiting

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT07046806Recruiting

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

NCT06343779Completed

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT05396105Enrolling by invitation

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT07266805Recruiting

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency